Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion

Neuro-Oncology

Volumn 14, Issue 5, 2012, Pages 641-648

  Crocker, Matthew ^a   Saadoun, Samira ^a   Jury, Alexa ^b   Jones, Chris ^b   Zacharoulis, Stergios ^b   Thomas, Samiwel ^c   Zwiggelaar, Reyer ^c   Bridges, Leslie R ^d   Bell, B Anthony ^a   Papadopoulos, Marios C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ABERYSTWYTH UNIVERSITY   (United Kingdom)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cerebral blood flow; Glioblastoma; Microvessel density; Necrosis; Xenon CT

Indexed keywords

CD31 ANTIGEN; XENON;

ADULT; ARTICLE; BRAIN BLOOD FLOW; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLIOBLASTOMA; HISTOGRAM; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; TUMOR NECROSIS; VASCULARIZATION;

ADULT; BRAIN NEOPLASMS; GLIOBLASTOMA; HUMANS; NECROSIS; NEOPLASM INVASIVENESS; PROGNOSIS; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR DISEASES; XENON;

EID: 84860368151     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos063     Document Type: Article

References (36)

1. Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic vessels of glioblastoma tumors. Expert Rev Mol Med. 2008;10:e23.
2. Kirsch M, Schackert G, Black PM. Anti-angiogenic treatment strategies for malignant brain tumors. J Neurooncol. 2000;50:149-163.
3. Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist. 2009;14:621-636.
4. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumors. Nat Rev Neurosci. 2007;8:610-622.
5. Batchelor TT, Sorensen AG, di Tomaso, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95.
6. Miletic H, Niclou SP, Johansson M, Bjerkvig R. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets. 2009;13:455-468.
7. Mladkova N, Chakravarti A. Molecular profiling in glioblastoma: prelude to personalized treatment. Curr Oncol Rep. 2009;11:53-61.
8. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
9. Brandsma D, van den Bent MJ. Molecular targeted therapies and chemotherapy in malignant gliomas. Curr Opin Oncol. 2007;19:598-605.
10. Hill C, Hunter SB, Brat DJ. Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol. 2003;10:212-217.
11. LoewS, SchmidtU,UnterbergA,HalatschME. Theepidermal growth factor receptor as a therapeutic target in glioblastomamultiforme and othermalignant neoplasms. Anticancer Agents Med Chem. 2009;9:703-715.
12. Waldman AD, Jackson A, Price SJ, et al. Quantitative imaging biomarkers in neuro-oncology. Nat Rev Clin Oncol. 2009;6:445-454.
13. Gerstner ER, Sorensen AG, Jain RK, Batchelor TT. Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas. Curr Opin Neurol. 2008;21:728-735.
14. Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am. 2009;19:527-557.
15. Bjornerud A, Sorensen AG, Mouridsen K, Emblem KE. T(1)-and T(2)(*)-dominant extravasation correction in DSC-MRI: part I-theoretical considerations and implications for assessment of tumor hemodynamic properties. J Cereb Blood Flow Metab. 2011;31:2041-2053.
16. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296-5300.
17. Basu S, Alavi A. Molecular imaging (PET) of brain tumors. Neuroimaging Clin N Am. 2009;19:625-646.
18. Duyn JH, van Gelderen P, Talagala L, Koretsky A, de Zwart JA. Technological advances in MRI measurement of brain perfusion. J Magn Reson Imaging. 2005;22:751-753.
19. Kety SS, Schmidt CF. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Clin Invest. 1948;27:476-483.
20. Yonas H, Gur D, Latchaw R, Wolfson SK, Jr. Stable xenon CT/CBF imaging: laboratory and clinical experience. Adv Tech Stand Neurosurg. 1987;15:3-37.
21. Chieregato A, Tanfani A, Noto A, Fronza S, Cocciolo F, Fainardi E. Cerebral blood flow thresholds predicting new hypoattenuation areas due to macrovascular ischemia during the acute phase of severe and complicated aneurysmal subarachnoid hemorrhage. A preliminary study. Acta Neurochir Suppl. 2008;102:311-316.
22. Ohashi M, Tsuji A, Kaneko M, Matsuda M. Threshold of regional cerebral blood flow for infarction in patients with acute cerebral ischemia. J Neuroradiol. 2005;32:337-341.
23. Nakagawa T, Tanaka R, Takeuchi S, Takeda N. Haemodynamic evaluation of cerebral gliomas using XeCT. Acta Neurochir (Wien). 1998;140:223-233; discussion 233-224.
24. Toglia A, Kittelson JM, Roemer RB, Hodak JA, Carter LP. Cerebral bloodflow in and around spontaneous malignant gliomas. Int J Hyperthermia. 1996;12:461-476.
25. Van Roost D, Hartmann A, Quade G. Changes of cerebral blood flow following dexamethasone treatment in brain tumor patients. A Xe/CT study. Acta Neurochir (Wien). 2001;143:37-43; discussion 43-34.
26. Crocker M, Ashley S, Giddings I, et al. Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol. 2011;13:99-108.
27. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23:291-299.
28. Pigott TJ, Lowe JS, Palmer J. Statistical modelling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg. 1991;5:61-66.
29. Lamszus K, Kunkel P, Westphal M. Invasion as limitation to antiangiogenic glioma therapy. Acta Neurochir Suppl. 2003;88:169-177.
30. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets. 2009;9:381-390.
31. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15:6683-6693.
32. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-198.
33. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009;92:317-335.
34. Kolenda J, Jensen SS, Aaberg-Jessen C, et al. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol. 2011;103:43-58.
35. Noch E, Khalili K. Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity. Cancer Biol Ther. 2009;8: 1791-1797.
36. Quarles CC, Gochberg DF, Gore JC, Yankeelov TE. A theoretical framework to model DSC-MRI data acquired in the presence of contrast agent extravasation. Phys Med Biol. 2009;54:5749-5766.